Document is current
Any future updates will be listed below
-
Authors
Laurikkala, Johanna http://orcid.org/0000-0002-6848-385X
Aneman, Anders
Peng, Alexander
Reinikainen, Matti
Pham, Paul
Jakkula, Pekka
Hästbacka, Johanna
Wilkman, Erika
Loisa, Pekka
Toppila, Jussi
Birkelund, Thomas
Blennow, Kaj
Zetterberg, Henrik
Skrifvars, Markus B.
-
Funding
Funding for this research was provided by:
Suomen Lääketieteen Säätiö
Medicinska Understödsföreningen Liv och Hälsa
Sigrid Juséliuksen Säätiö
Finska Läkaresällskapet
- License Information
-
More Information
Article History
Received: 2 June 2021
Accepted: 9 September 2021
First Online: 28 September 2021
Declarations
:
: The COMACARE study protocol was approved by the research ethics committees of the Northern Savo District, Finland (Decision No. 295/2015) and the Midtjylland region, Denmark (Decision No. 1-10-72-163-16). In addition, the trial protocol was approved by the institutional review board at each participating hospital.
: Not applicable.
: HZ has served at scientific advisory boards for Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies and CogRx, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). Markus Skrifvars reports a lecture fee and travel grant from BARD Medical (Ireland). Erika Wilkman reports an external research support agreement (Research-Devices Grant, INVOS) with Medtronic (Covidien Ag).
